A multinational team has used anti-CD20 mAbs to treat heart attacks by depleting inflammation-causing CD20+ B cells at the infarct site. The researchers are planning a Phase IIa trial of Rituxan in MI, and at least one biotech with an anti-CD20 antibody is discussing the findings with its pharma partner.